Literature DB >> 28448702

Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action.

Chittaranjan Andrade1.   

Abstract

Ketamine is an anesthetic drug that is also used for off-label indications such as the mediation of analgesia and sedation in various settings. It is additionally recognized as an agent with antidepressant potential. For depression, it is most commonly administered as a slow intravenous infusion in subanesthetic doses (usually 0.5 mg/kg). As an antidepressant, is strikingly different from conventional antidepressant drugs in that it brings about rapid and marked attenuation of depressive symptoms even in patients with refractory depression. The benefits are observed within hours of administration, peak after about a day, and are lost 3-12 days later. Patients who do not benefit after the initial dose may benefit with serial dosing or at higher doses. Benefits can be maintained for weeks to months by the continuation of ketamine sessions at 2- to 4-day intervals. Adverse effects include dissociative and psychotomimetic changes that are almost always mild and transient, if present; transient elevation of heart rate and blood pressure often occur. These changes are usually well tolerated and are very seldom responsible for treatment discontinuation. Whereas ketamine is an N-methyl-d-aspartate receptor antagonist, and whereas much is known about its different biological effects, its actions that mediate the antidepressant response are presently not known for certain. Although big data on ketamine are presently unavailable, the drug holds promise in the treatment of depression, especially refractory depression. © Copyright 2017 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28448702     DOI: 10.4088/JCP.17f11567

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

1.  Ketamine treatment protects against oxidative damage and the immunological response induced by electroconvulsive therapy.

Authors:  Cinara Ludvig Gonçalves; Helena Mendes Abelaira; Thayse Rosa; Airam Barbosa de Moura; Deise Cristina Veron; Laura Araújo Borba; Maria Eduarda Mendes Botelho; Mariana Pereira Goldim; Leandro Garbossa; Maria Eduarda Fileti; Fabricia Petronilho; Zuleide Maria Ignácio; João Quevedo; Gislaine Zilli Réus
Journal:  Pharmacol Rep       Date:  2021-01-03       Impact factor: 3.024

2.  Effect of Psilocybin and Ketamine on Brain Neurotransmitters, Glutamate Receptors, DNA and Rat Behavior.

Authors:  Adam Wojtas; Agnieszka Bysiek; Agnieszka Wawrzczak-Bargiela; Zuzanna Szych; Iwona Majcher-Maślanka; Monika Herian; Marzena Maćkowiak; Krystyna Gołembiowska
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

Review 3.  Can seizure therapies and noninvasive brain stimulations prevent suicidality? A systematic review.

Authors:  Yiming Chen; Charline Magnin; Jérome Brunelin; Edouard Leaune; Yiru Fang; Emmanuel Poulet
Journal:  Brain Behav       Date:  2021-04-10       Impact factor: 2.708

4.  Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.

Authors:  Tony Ye; Mitchell J Bartlett; Scott J Sherman; Torsten Falk; Stephen L Cowen
Journal:  Exp Neurol       Date:  2021-03-02       Impact factor: 5.620

Review 5.  Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder.

Authors:  Carola Rong; Caroline Park; Joshua D Rosenblat; Mehala Subramaniapillai; Hannah Zuckerman; Dominika Fus; Yena L Lee; Zihang Pan; Elisa Brietzke; Rodrigo B Mansur; Danielle S Cha; Leanna M W Lui; Roger S McIntyre
Journal:  Int J Environ Res Public Health       Date:  2018-04-17       Impact factor: 3.390

6.  A possible role for ketamine in suicide prevention in emergency and mainstream psychiatry.

Authors:  T S Sathyanarayana Rao; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2017 Jul-Sep       Impact factor: 1.759

7.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

Review 8.  Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.

Authors:  Felicia Ceban; Joshua D Rosenblat; Kevin Kratiuk; Yena Lee; Nelson B Rodrigues; Hartej Gill; Mehala Subramaniapillai; Flora Nasri; Leanna M W Lui; Orly Lipsitz; Anil Kumar; Jung Goo Lee; Edmond H Chau; Bing Cao; Kangguang Lin; Roger C Ho; Rodrigo B Mansur; Jennifer Swainson; Roger S McIntyre
Journal:  CNS Drugs       Date:  2021-08-07       Impact factor: 5.749

Review 9.  Biological Mechanisms of Cancer-Induced Depression.

Authors:  Kimberly Young; Gurmit Singh
Journal:  Front Psychiatry       Date:  2018-07-10       Impact factor: 4.157

Review 10.  Brain-Derived Neurotrophic Factor and Major Depressive Disorder: Evidence from Meta-Analyses.

Authors:  Taro Kishi; Reiji Yoshimura; Toshikazu Ikuta; Nakao Iwata
Journal:  Front Psychiatry       Date:  2018-01-17       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.